A giant pharmaceutical company consulted Bioviser for the purpose of presenting the late-breaking results of a phase 2, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy and safety of a monoclonal antibody in atopic dermatitis at two major dermatology conferences (one in Europe and another in the US).
APPROACH
In view of the late-breaking nature of the results, demanding author group, and stringent timelines, we collated a team of experts in epidemiology, pharmacology, medical writing, and graphics; this team worked on both the presentations. Based on the initial guidance provided by the author group, the team captured the author group’s visualizations and sought clarifications in advance to make the process efficient and save the authors’ time. The team simultaneously worked on different tasks to meet client expectations on both the presentations in a timely manner.